This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is funding research at Harvard Medical School to investigate the mechanisms by which the enzyme UBE2O mediates protein quality control and ribosome homeostasis during red blood cell differentiation. The $616,914 award will support experimental and structural studies to reconstitute UBE2O-dependent proteasomal degradation of substrates, explore how adaptor proteins influence UBE2O targeting, and identify new factors that work with UBE2O to degrade entire ribosomes. Successful completion of these aims is expected to elucidate unique quality control and ribosome homeostasis mechanisms within the ubiquitin-proteasome system that are essential for red blood cell production and function. As a sub-grantee, Harvard Medical School has also contributed expertise in areas like structural biology, data visualization, and healthcare policy research to federally funded projects at other institutions.
Generated 2/25/25, 3:00 AM